


Bhanvadia et al. Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities

APPENDIX

Supplementary Figure 1. Patient selection map.



Supplementary Figure 2. Kaplan-Meier analysis of overall survival stratified by hospital safety net status and treatment approach.




Figure legend: Supplementary Figure 2 shows Kaplan-Meier overall survival curves of patients with localized high risk prostate cancer stratified by SNH status (orange lines) vs non-SNH status (blue lines), and by treatment approach of RP/RT (solid lines), no treatment (short-dashed lines), and ADT monotherapy (long dashed lines).

Bhanvadia et al. Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities

Supplementary Table 1. Multivariable logistic regression model of odds of non-curative treatment of patients age <65, and one or less comorbidity			
Variable (N=35 802)	Odds ratio	p	95% confidence interval
Safety net burden			
Low	Ref.	Ref.	Ref.
High	2.32	<0.01	2.06–2.62
Race			
White	Ref.	Ref.	Ref.
Black	1.50	<0.01	1.36–1.65
Other	1.29	<0.01	1.07–1.57
Clinical T stage			
T1	Ref.	Ref.	Ref.
T2	0.74	<0.01	0.67–0.83
T3	0.76	<0.01	0.65–0.89
PSA	1.001	<0.01	1.001–1.001
Sum Gleason grade			
6	Ref.	Ref.	Ref.
7	0.31	<0.01	0.28–0.36
8–10	0.38	<0.01	0.34–0.42
Median income quartile			
\$0–29 999	Ref.	Ref.	Ref.
\$30 000–34 999	0.91	0.17	0.79–1.04
\$35 000–45 999	0.77	<0.01	0.68–0.87
\$46 000+	0.70	<0.01	0.61–0.79
Hospital type			
Community cancer program	Ref.	Ref.	Ref.
Comprehensive community cancer program	0.49	<0.01	0.42–0.57
Academic program	0.78	<0.01	0.64–0.85
Integrated network cancer program	0.43	<0.01	0.36–0.53
Year	1.09	<0.01	1.06–1.11

Bhanvadia et al. Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities

Supplementary Table 2. Multivariable logistic regression model of odds of non-curative treatment of patients with private insurance			
Variable (N= 33 605)	Odds ratio	p	95% confidence interval
Safety net burden			
Low	Ref.	Ref.	Ref.
High	2.19	<0.01	1.90–2.57
Age	1.07	<0.01	1.06–1.08
Race			
White	Ref.	Ref.	Ref.
Black	1.62	<0.01	1.45–1.80
Other	1.33	<0.01	1.10–1.61
Charlson comorbidity scores			
0	Ref.	Ref.	Ref.
1	0.84	0.02	0.73–0.97
>2	1.35	0.01	1.06–1.71
Clinical T stage			
T1	Ref.	Ref.	Ref.
T2	0.77	<0.01	0.69–0.86
T3	0.76	<0.01	0.65–0.90
Prostate-specific antigen*	1.001	<0.01	1.001–1.001
Sum Gleason grade			
6	Ref.	Ref.	Ref.
7	0.32	<0.01	0.28–0.37
8-10	0.29	<0.01	0.26–0.33
Median income quartile			
\$0–29 999	Ref.	Ref.	Ref.
\$30 000–34 999	1.08	0.36	0.92–1.27
\$35,000–45 999	0.87	0.09	0.75–1.02
\$46 000+	0.80	<0.01	0.69–0.92
Hospital type			
Community cancer program	Ref.	Ref.	Ref.
Comprehensive community cancer program	0.54	<0.01	0.46–0.64
Academic program	0.86	0.06	0.73–1.01
Integrated network cancer program	0.43	<0.01	0.34– 0.53
Year	1.11	<0.01	1.08–1.13

Bhanvadia et al. Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities

Supplemental Table 3. Multivariable logistic regression model of odds of non-curative treatment of patients treated at academic centers			
Variable (N=32 320)	Odds ratio	p	95% confidence interval
Safety net burden			
Low	Ref.	Ref.	Ref.
High	1.87	<0.01	1.69–2.06
Age	1.08	<0.01	1.07–1.08
Race			
White	Ref.	Ref.	Ref.
Black	1.69	<0.01	1.54–1.85
Other	1.16	0.04	1.00–1.35
Charlson comorbidity scores			
0	Ref.	Ref.	Ref.
1	0.84	<0.01	0.75–0.94
>2	1.14	0.14	0.96–1.37
Clinical T stage			
T1	Ref.	Ref.	Ref.
T2	0.72	<0.01	0.66–0.79
T3	0.76	<0.01	0.66–0.85
PSA	1.001	<0.01	1.001–1.001
Sum Gleason grade			
6	Ref.	Ref.	Ref.
7	0.29	<0.01	0.25–0.32
8-10	0.28	<0.01	0.25–0.31
Median income quartile			
\$0–29 999	Ref.	Ref.	Ref.
\$30 000–34 999	0.81	<0.01	0.71–0.92
\$35 000–45 999	0.79	<0.01	0.70–0.89
\$46 000+	0.74	<0.01	0.66–0.83
Year	1.05	<0.01	1.03–1.07

Bhanvadia et al. Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities

Supplementary Table 4. Multivariable Cox proportional hazards model of overall survival among patients who underwent treatment with curative intent			
Variable (N=69 874)	Hazard ratio	p	95% confidence interval
Safety net hospital status			
Non-safety net hospital	Ref.	Ref.	Ref.
Safety net hospital	1.02	0.77	0.88–1.17
Age	1.06	<0.01	1.05–1.06
Race			
White	Ref.	Ref.	Ref.
Black	1.17	<0.01	1.08–1.26
Other	0.68	<0.01	0.58–0.80
Charlson comorbidity scores			
0	Ref.	Ref.	Ref.
1	1.34	<0.01	1.25–1.43
≥2	1.98	<0.01	1.77–2.21
Clinical T stage			
T1	Ref.	Ref.	Ref.
T2	1.18	<0.01	1.11–1.25
T3	1.46	<0.01	1.34–1.58
Prostate-specific antigen	1.001	<0.01	1.00–1.00
Sum Gleason grade			
6	Ref.	Ref.	Ref.
7	1.50	<0.01	1.30–1.73
8–10	2.20	<0.01	1.92–2.51
Median income quartile			
\$0–29 999	Ref.	Ref.	Ref.
\$30 000–34 999	0.96	0.11	0.88–1.05
\$35 000–45 999	0.92	0.06	0.84–1.00
\$46 000+	0.81	<0.01	0.73–0.90
Percent no high school education			
>17.5%	Ref.	Ref.	Ref.
10.9–17.5%	1.07	0.11	0.98–1.15
6.3–10.8%	0.96	0.35	0.88–1.05
<6.3%	0.92	0.09	0.83–1.01
U.S. region			
West	Ref.	Ref.	Ref.

Bhanvadia et al. Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities

Midwest	1.12	<0.01	1.02–1.22
South	1.12	<0.01	1.03–1.22
Northeast	1.02	0.72	0.93–1.11
Hospital type			
Community cancer program	Ref.	Ref.	Ref.
Comprehensive community cancer program	0.89	<0.01	0.81–0.97
Academic program	0.72	<0.01	0.66–0.80
Integrated network cancer program	0.83	<0.01	0.74–0.92
Year	1.02	0.03	1.00–1.04

Supplementary Table 5. Multivariable Cox proportional hazards model of overall survival among patients who underwent non-curative intent treatment			
Variable (N=6583)	Hazard ratio	p	95% confidence interval
Safety net hospital status			
Non-Safety net hospital	Ref.	Ref.	Ref.
Safety net hospital	0.82	0.02	0.69–0.74
Age	1.05	<0.01	1.04–1.06
ADT use			
No	Ref.	Ref.	Ref.
Yes	1.00	0.98	0.90–1.12
Race			
White	Ref.	Ref.	Ref.
Black	1.03	0.63	1.14–1.48
Other	0.74	0.02	0.57–0.95
Charlson comorbidity scores			
0	Ref.	Ref.	Ref.
1	1.30	<0.01	1.14–1.48
≥2	2.13	<0.01	1.81–2.53
Clinical T stage			
T1	Ref.	Ref.	Ref.
T2	1.03	0.56	0.92–1.16
T3	1.03	0.77	0.86–1.23
PSA	1.001	< 0.01	1.00–1.00
Sum Gleason grade			
6	Ref.	Ref.	Ref.

Bhanvadia et al. Understanding the hospital safety net: Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities

7	2.44	<0.01	1.94–3.07
8–10	3.44	<0.01	2.78–4.27
Median income quartile			
\$0–29 999	Ref.	Ref.	Ref.
\$30 000–34 999	1.13	0.12	0.97–1.34
\$35 000–45 999	1.06	0.47	0.90–1.25
\$46 000+	1.07	0.47	0.89–1.29
Percent no high school education			
>17.5%	Ref.	Ref.	Ref.
10.9–17.5%	1.00	0.99	0.87–1.15
6.3–10.8%	0.84	0.04	0.71–0.99
<6.3%	0.89	0.22	0.73–1.08
U.S. region			
West	Ref.	Ref.	Ref.
Midwest	1.39	<0.01	1.17–1.65
South	1.24	0.01	1.05–1.48
Northeast	1.13	0.20	0.94–1.37
Hospital type			
Community cancer program	Ref.	Ref.	Ref.
Comprehensive community cancer program	0.91	0.23	0.78–1.06
Academic program	0.71	< 0.01	0.61–0.84
Integrated network cancer program	1.01	0.93	0.82–1.24
Year	1.02	0.18	0.99–1.06